MetLife Investment Management LLC Acquires 10,056 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

MetLife Investment Management LLC increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.9% during the 4th quarter, HoldingsChannel reports. The firm owned 179,555 shares of the biopharmaceutical company’s stock after purchasing an additional 10,056 shares during the period. MetLife Investment Management LLC’s holdings in Amicus Therapeutics were worth $1,691,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. HealthInvest Partners AB lifted its stake in Amicus Therapeutics by 18.6% in the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock valued at $3,076,000 after buying an additional 51,368 shares in the last quarter. Tempus Wealth Planning LLC bought a new stake in Amicus Therapeutics in the 4th quarter valued at $259,000. Intech Investment Management LLC boosted its stake in Amicus Therapeutics by 59.7% in the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock worth $1,175,000 after purchasing an additional 46,633 shares during the period. Norges Bank acquired a new position in Amicus Therapeutics in the 4th quarter worth $29,033,000. Finally, Renaissance Technologies LLC raised its stake in shares of Amicus Therapeutics by 174.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company’s stock valued at $19,863,000 after purchasing an additional 1,339,316 shares during the period.

Amicus Therapeutics Stock Up 1.8 %

Amicus Therapeutics stock opened at $7.52 on Wednesday. Amicus Therapeutics, Inc. has a fifty-two week low of $6.20 and a fifty-two week high of $12.65. The firm has a market capitalization of $2.31 billion, a PE ratio of -41.78, a P/E/G ratio of 1.51 and a beta of 0.79. The company’s 50-day moving average is $8.08 and its 200-day moving average is $9.36. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Wall Street Analyst Weigh In

FOLD has been the subject of several recent research reports. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.